Somanta Pharmaceuticals Overview
- Year Founded
-
2001
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
Somanta Pharmaceuticals General Information
Description
Developer of biotechnology drugs for cancer treatment. The company's pre-clinical drugs include Angiolix, a humanized monoclonal antibody that induces programmed cell death, or apoptosis, in blood vessels supporting tumors, Prodrax, a molecule that is non-toxic in normally oxygenated healthy tissue but becomes highly toxic in low oxygen tumors where it binds to the DNA in tumor cells and becomes irreversibly converted to its toxic form; and Alchemix which is intended to interrupt various phases of the cancer cell growth cycle by selectively binding to DNA (Deoxyribonucleic acid) and inhibiting DNA processing enzymes to overcome drug resistant tumors.
Contact Information
Website
www.somanta.comCorporate Office
- 19200 Von Karman Avenue
- Suite 400
- Irvine, CA 92612
- United States
Corporate Office
- 19200 Von Karman Avenue
- Suite 400
- Irvine, CA 92612
- United States
Somanta Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 07-Jan-2008 | Completed | Clinical Trials - Phase 2 | |||
| 2. Reverse Merger | 01-Feb-2006 | Completed | Generating Revenue | |||
| 1. Early Stage VC | 01-Jan-2006 | $4.9M | $4.9M | Completed | Generating Revenue |
Somanta Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Somanta Pharmaceuticals Patents
Somanta Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20070208085-A1 | Potent cytotoxicity and inhibition of pan-cell cycle progression by an alkylating anthraquinone | Inactive | 17-Jan-2006 |
Somanta Pharmaceuticals Former Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alpha Capital Partners | PE/Buyout | Minority | ||
| Hibshman Optical | Corporation | Minority | ||
| Whalehaven Capital Fund | Venture Capital | Minority | ||
| Xmark Asset Management | Venture Capital | Minority |
Somanta Pharmaceuticals Acquisitions (1)
Somanta Pharmaceuticals’s most recent deal was a Merger/Acquisition with Hibshman Optical. The deal was made on 31-Jan-2006.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Hibshman Optical | 31-Jan-2006 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Somanta Pharmaceuticals FAQs
-
When was Somanta Pharmaceuticals founded?
Somanta Pharmaceuticals was founded in 2001.
-
Where is Somanta Pharmaceuticals headquartered?
Somanta Pharmaceuticals is headquartered in Irvine, CA.
-
What industry is Somanta Pharmaceuticals in?
Somanta Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Somanta Pharmaceuticals a private or public company?
Somanta Pharmaceuticals is a Private company.
-
What is Somanta Pharmaceuticals’s current revenue?
The current revenue for Somanta Pharmaceuticals is .
-
How much funding has Somanta Pharmaceuticals raised over time?
Somanta Pharmaceuticals has raised $4.9M.
-
Who are Somanta Pharmaceuticals’s investors?
Alpha Capital Partners, Hibshman Optical, Whalehaven Capital Fund, and Xmark Asset Management have invested in Somanta Pharmaceuticals.
-
When was Somanta Pharmaceuticals acquired?
Somanta Pharmaceuticals was acquired on 07-Jan-2008.
-
Who acquired Somanta Pharmaceuticals?
Somanta Pharmaceuticals was acquired by Abeona Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
